Ultragenyx to Participate at Investor Conferences in March

On February 27, 2024 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, reported that management will be participating in three upcoming investor conferences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

44th Annual Cowen Healthcare Conference (Boston, MA)

Monday, March 4, 2024, Eric Crombez, M.D., Chief Medical Officer, will participate in a fireside chat and host 1×1 meetings.
Leerink Partners Global Biopharma Conference (Miami, FL)

Tuesday, March 12, 2024, Emil Kakkis, M.D., Ph.D., CEO and President and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1×1 meetings.
Barclays 26th Annual Global Healthcare Conference (Miami, FL)

Wednesday, March 13, 2024, Emil Kakkis and Howard Horn will participate in a fireside chat and host 1×1 meetings.
The live and archived webcast of the fireside chat will be accessible from the company’s website at View Source